A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

INTRODUCTION: We previously demonstrated that 1 or 5 mg per day of tamoxifen (T) given for four weeks before surgery reduces Ki-67 in breast cancer (BC) patients to the same extent as the standard 20 mg/d. Given the long half-life of T, a weekly dose (10 mg per week (w)) may be worth testing. Also,...

Descripción completa

Detalles Bibliográficos
Autores principales: Serrano, Davide, Lazzeroni, Matteo, Gandini, Sara, Macis, Debora, Johansson, Harriet, Gjerde, Jennifer, Lien, Ernst, Feroce, Irene, Pruneri, Giancarlo, Sandri, Maria Teresa, Bassi, Fabio, Brenelli, Fabricio, Luini, Alberto, Cazzaniga, Massimiliano, Varricchio, Clara, Guerrieri-Gonzaga, Aliana, DeCensi, Andrea, Bonanni, Bernardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053157/
https://www.ncbi.nlm.nih.gov/pubmed/23786776
http://dx.doi.org/10.1186/bcr3439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053157/
https://www.ncbi.nlm.nih.gov/pubmed/23786776
http://dx.doi.org/10.1186/bcr3439

Ejemplares similares